These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 31707538)

  • 1. Reconciling the distinct roles of angiogenic/anti-angiogenic factors in the placenta and maternal circulation of normal and pathological pregnancies.
    Umapathy A; Chamley LW; James JL
    Angiogenesis; 2020 May; 23(2):105-117. PubMed ID: 31707538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Placental growth factor reverses decreased vascular and uteroplacental MMP-2 and MMP-9 and increased MMP-1 and MMP-7 and collagen types I and IV in hypertensive pregnancy.
    Ren Z; Cui N; Zhu M; Khalil RA
    Am J Physiol Heart Circ Physiol; 2018 Jul; 315(1):H33-H47. PubMed ID: 29569955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levels of serum-circulating angiogenic factors within 1 week prior to delivery are closely related to conditions of pregnant women with pre-eclampsia, gestational hypertension, and/or fetal growth restriction.
    Nanjo S; Minami S; Mizoguchi M; Yamamoto M; Yahata T; Toujima S; Shiro M; Kobayashi A; Muragaki Y; Ino K
    J Obstet Gynaecol Res; 2017 Dec; 43(12):1805-1814. PubMed ID: 28929598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders.
    Khalil A; Muttukrishna S; Harrington K; Jauniaux E
    PLoS One; 2008 Jul; 3(7):e2766. PubMed ID: 18648513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The vascular endothelial growth factor family in adverse pregnancy outcomes.
    Andraweera PH; Dekker GA; Roberts CT
    Hum Reprod Update; 2012 Jul; 18(4):436-57. PubMed ID: 22495259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maternal and foetal angiogenic imbalance in congenital heart defects.
    Llurba E; Sánchez O; Ferrer Q; Nicolaides KH; Ruíz A; Domínguez C; Sánchez-de-Toledo J; García-García B; Soro G; Arévalo S; Goya M; Suy A; Pérez-Hoyos S; Alijotas-Reig J; Carreras E; Cabero L
    Eur Heart J; 2014 Mar; 35(11):701-7. PubMed ID: 24159191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenic Imbalance as a Contributor of Preeclampsia.
    Dymara-Konopka W; Laskowska M; Błażewicz A
    Curr Pharm Biotechnol; 2018; 19(10):797-815. PubMed ID: 30255753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Potential value of placental angiogenic factors as biomarkers in preeclampsia for clinical physicians].
    Boulanger H; Lefèvre G; Ahriz Saksi S; Achiche J; Bailleul S; Ekoukou D; Drouin D; Sault C; Stawiarski N; Dupuis E
    Nephrol Ther; 2019 Nov; 15(6):413-429. PubMed ID: 30935786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discordant clinical presentations of preeclampsia and intrauterine fetal growth restriction with similar pro- and anti-angiogenic profiles.
    Alahakoon TI; Zhang W; Trudinger BJ; Lee VW
    J Matern Fetal Neonatal Med; 2014 Dec; 27(18):1854-9. PubMed ID: 24397483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II and angiotensin-(1-7) decrease sFlt1 release in normal but not preeclamptic chorionic villi: an in vitro study.
    Anton L; Merrill DC; Neves LA; Gruver C; Moorefield C; Brosnihan KB
    Reprod Biol Endocrinol; 2010 Nov; 8():135. PubMed ID: 21050477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Placental Growth Factor Administration Abolishes Placental Ischemia-Induced Hypertension.
    Spradley FT; Tan AY; Joo WS; Daniels G; Kussie P; Karumanchi SA; Granger JP
    Hypertension; 2016 Apr; 67(4):740-7. PubMed ID: 26831193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia.
    Aggarwal PK; Chandel N; Jain V; Jha V
    J Hum Hypertens; 2012 Apr; 26(4):236-41. PubMed ID: 21451568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies.
    Holme AM; Roland MC; Henriksen T; Michelsen TM
    Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia--a step forward but not the definitive answer.
    Foidart JM; Schaaps JP; Chantraine F; Munaut C; Lorquet S
    J Reprod Immunol; 2009 Nov; 82(2):106-11. PubMed ID: 19853925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prediction of fetal death with a simple maternal blood test at 20-24 weeks: a role for angiogenic index-1 (PlGF/sVEGFR-1 ratio).
    Chaiworapongsa T; Romero R; Erez O; Tarca AL; Conde-Agudelo A; Chaemsaithong P; Kim CJ; Kim YM; Kim JS; Yoon BH; Hassan SS; Yeo L; Korzeniewski SJ
    Am J Obstet Gynecol; 2017 Dec; 217(6):682.e1-682.e13. PubMed ID: 29037482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Placental growth factor (PlGF) and sFlt-1 during pregnancy: physiology, assay and interest in preeclampsia.
    Lecarpentier É; Vieillefosse S; Haddad B; Fournier T; Leguy MC; Guibourdenche J; Tsatsaris V
    Ann Biol Clin (Paris); 2016 Jun; 74(3):259-67. PubMed ID: 27237799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of anti-hypertensive drugs on production of soluble fms-like tyrosine kinase 1 and soluble endoglin from human normal and pre-eclamptic placentas in vitro.
    Xu B; Thornton C; Tooher J; Ogle R; Lim S; Makris A; Hennessy A
    Clin Exp Pharmacol Physiol; 2009 Aug; 36(8):839-42. PubMed ID: 19215236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia.
    Govender N; Naicker T; Rajakumar A; Moodley J
    Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):100-5. PubMed ID: 23806447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
    Brownfoot FC; Hastie R; Hannan NJ; Cannon P; Tuohey L; Parry LJ; Senadheera S; Illanes SE; Kaitu'u-Lino TJ; Tong S
    Am J Obstet Gynecol; 2016 Mar; 214(3):356.e1-356.e15. PubMed ID: 26721779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate.
    Romero R; Nien JK; Espinoza J; Todem D; Fu W; Chung H; Kusanovic JP; Gotsch F; Erez O; Mazaki-Tovi S; Gomez R; Edwin S; Chaiworapongsa T; Levine RJ; Karumanchi SA
    J Matern Fetal Neonatal Med; 2008 Jan; 21(1):9-23. PubMed ID: 18175241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.